News & ResourcesCurrus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001
June 2026
Victoria Sharp on Awareness and her Hope for Better Outcomes in Cancer Care
National Cancer Survivors Day Survivor 7th June – Q&A
October 2023
Currus Biologics builds out clinical advisory team
Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology has further expanded its clinical advisory team as it advances towards a first in human clinical trial.
October 2022
BIO-Europe 2022 Attendance
Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology will attend this year’s BIO-Europe Convention.
February 2022
Currus Biologics Best Newcomer award Governor of Victoria Start-up Awards Melbourne, Australia
Currus Biologics is excited to announce that it has been named Best Newcomer of the Year in the inaugural Governor of Victoria Start-up Awards.
June 2021
$10m invested into start-up developing new treatments targeting the use of CAR-T cell therapies against solid tumours
Currus Biologics raises $10 million Series A investment from leading life science Venture Capital investors.
September 2022
Presentation at CAR-TCR Summit
Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology has further expanded its clinical advisory team as it advances towards a first in human clinical trial.
September 2021
Currus Biologics researchers publish in high impact journal, Journal for ImmunoTherapy of Cancer
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. Journal for ImmunoTherapy of Cancer 2021;9:e002555. doi: 10.1136/jitc-2021-002555